TY - JOUR
T1 - Do Vasodilators Prolong Life in Heart Failure?
AU - Packer, M.
PY - 1987/6/4
Y1 - 1987/6/4
N2 - Over the past decade, vasodilator therapy has become an accepted way to treat the symptoms of patients with congestive heart failure. By antagonizing the systemic vasoconstriction that limits cardiac performance, vasodilator drugs alter the loading conditions in the failing left ventricle and can thereby produce immediate and long-term hemodynamic and clinical improvement.1 Yet, despite these symptomatic benefits, the prognosis of patients with chronic heart failure remains extremely poor. The annual mortality rate ranges from 15 to 60 percent, depending on the severity of the underlying disease. Nearly 200,000 patients die of heart failure in the United States each year. Do…
AB - Over the past decade, vasodilator therapy has become an accepted way to treat the symptoms of patients with congestive heart failure. By antagonizing the systemic vasoconstriction that limits cardiac performance, vasodilator drugs alter the loading conditions in the failing left ventricle and can thereby produce immediate and long-term hemodynamic and clinical improvement.1 Yet, despite these symptomatic benefits, the prognosis of patients with chronic heart failure remains extremely poor. The annual mortality rate ranges from 15 to 60 percent, depending on the severity of the underlying disease. Nearly 200,000 patients die of heart failure in the United States each year. Do…
UR - http://www.scopus.com/inward/record.url?scp=0023643857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023643857&partnerID=8YFLogxK
U2 - 10.1056/NEJM198706043162308
DO - 10.1056/NEJM198706043162308
M3 - Editorial
C2 - 3033507
AN - SCOPUS:0023643857
SN - 0028-4793
VL - 316
SP - 1471
EP - 1473
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 23
ER -